Vo K - Search Results

1

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.

Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. Goldsmith KC, et al. Among authors: vo k. Nat Med. 2023 May;29(5):1092-1102. doi: 10.1038/s41591-023-02297-5. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012551 Free PMC article. Clinical Trial.

2

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. Vo KT, et al. J Clin Oncol. 2014 Oct 1;32(28):3169-76. doi: 10.1200/JCO.2014.56.1621. Epub 2014 Aug 25. J Clin Oncol. 2014. PMID: 25154816 Free PMC article.

3

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.

Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG. Thompson D, et al. Among authors: vo kt. Cancer. 2016 Mar 15;122(6):935-45. doi: 10.1002/cncr.29848. Epub 2015 Dec 28. Cancer. 2016. PMID: 26709890 Free PMC article.

4

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma.

Vo KT, Matthay KK, DuBois SG. Vo KT, et al. Clin Sarcoma Res. 2016 Jun 7;6:9. doi: 10.1186/s13569-016-0049-z. eCollection 2016. Clin Sarcoma Res. 2016. PMID: 27274393 Free PMC article. Review.

5

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.

Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, Maris JM, Weiss B, Marachelian A, Yanik GA, Matthay KK. Huibregtse KE, et al. Among authors: vo kt. Eur J Cancer. 2016 Oct;66:144-52. doi: 10.1016/j.ejca.2016.07.017. Epub 2016 Aug 27. Eur J Cancer. 2016. PMID: 27573428 Free PMC article. Clinical Trial.

6

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.

Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG. Vo KT, et al. Oncotarget. 2017 Apr 4;8(14):23851-23861. doi: 10.18632/oncotarget.12904. Oncotarget. 2017. PMID: 27793021 Free PMC article. Clinical Trial.

7

Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for ¹³¹ I-MIBG therapy of neuroblastoma using ¹²⁴ I-MIBG PET/CT.

Seo Y, Huh Y, Huang SY, Hernandez-Pampaloni JM, Hawkins RA, Gustafson WC, Vo KT, Matthay KK. Seo Y, et al. Among authors: vo kt. Med Phys. 2019 May;46(5):2477-2486. doi: 10.1002/mp.13446. Epub 2019 Mar 12. Med Phys. 2019. PMID: 30761545 Free PMC article.

8

Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.

Tolbert VP, Dvorak CC, Golden C, Vissa M, El-Haj N, Perwad F, Matthay KK, Vo KT. Tolbert VP, et al. Among authors: vo kt. Biol Blood Marrow Transplant. 2019 Oct;25(10):2031-2039. doi: 10.1016/j.bbmt.2019.06.006. Epub 2019 Jun 12. Biol Blood Marrow Transplant. 2019. PMID: 31199983 Free PMC article.

9

¹²⁴I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma.

Aboian MS, Huang SY, Hernandez-Pampaloni M, Hawkins RA, VanBrocklin HF, Huh Y, Vo KT, Gustafson WC, Matthay KK, Seo Y. Aboian MS, et al. Among authors: vo kt. J Nucl Med. 2021 Jan;62(1):43-47. doi: 10.2967/jnumed.120.243139. Epub 2020 May 15. J Nucl Med. 2021. PMID: 32414950 Free PMC article.

10

Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma.

Temple WC, Vo KT, Matthay KK, Balliu B, Coleman C, Michlitsch J, Phelps A, Behr S, Zapala MA. Temple WC, et al. Among authors: vo kt. Cancer Med. 2021 Apr;10(7):2232-2241. doi: 10.1002/cam4.3663. Epub 2020 Dec 13. Cancer Med. 2021. PMID: 33314708 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

375 results

Search Page

Filters